[1]
|
薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227.
|
[2]
|
Powell, E.E., Wong, V.W. and Rinella, M. (2021) Non-Alcoholic Fatty Liver Disease. The Lancet, 397, 2212-2224.
https://doi.org/10.1016/S0140-6736(20)32511-3
|
[3]
|
Erickson, S.K. (2009) Nonalcoholic Fatty Liver Disease. Journal of Lipid Research, 50, S412-S416.
https://doi.org/10.1194/jlr.R800089-JLR200
|
[4]
|
Younossi, Z., Anstee, Q.M., Marietti, M., et al. (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 15, 11-20.
https://doi.org/10.1038/nrgastro.2017.109
|
[5]
|
Bessone, F., Razori, M.V. and Roma, M.G. (2019) Molecular Pathways of Nonalcoholic Fatty Liver Disease Development and Progression. Cellular and Molecular Life Sciences, 76, 99-128. https://doi.org/10.1007/s00018-018-2947-0
|
[6]
|
Mao, X.H., Liu, Z.Q., Shi, O.M., et al. (2021) Non-Invasive Fibrosis Markers Are Associated with Mortality Risk in both General Populations and Non-Alcoholic Fatty Liver Disease Patients. Hepatology Research, 51, 90-101.
https://doi.org/10.1111/hepr.13570
|
[7]
|
Ogden, C.L., Carroll, M.D., Kit, B.K. and Flegal, K.M. (2012) Prevalence of Obesity and Trends in Body Mass Index among US Children and Adolescents, 1999-2010. JAMA, 307, 483-490. https://doi.org/10.1001/jama.2012.40
|
[8]
|
McPherson, S., Hardy, T., Henderson, E., Burt, A.D., Day, C.P. and Anstee, Q.M. (2015) Evidence of NAFLD Progression from Steatosis to Fibrosing-Steatohepatitis Using Paired Biop-sies: Implications for Prognosis and Clinical Management. Journal of Hepatology, 62, 1148-1155. https://doi.org/10.1016/j.jhep.2014.11.034
|
[9]
|
Singh, S., Allen, A.M., Wang, Z., et al. (2015) Fibrosis Progres-sion in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology, 13, 643-654.e9. https://doi.org/10.1016/j.cgh.2014.04.014
|
[10]
|
Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. (2015) Liver Fi-brosis, but No Other Histologic Features, Is Associated with Long-Term Outcomes of Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology, 149, 389- 397.e10. https://doi.org/10.1053/j.gastro.2015.04.043
|
[11]
|
冷雪君, 颜学兵. FibroTouch无创肝脏硬度测定值与血清标志物对慢性乙型肝炎患者肝纤维化程度评估的相关性分析[J]. 世界华人消化杂志, 2018, 26(12): 707-715.
|
[12]
|
Nalbantoglu, I.L. and Brunt, E.M. (2014) Role of Liver Biopsy in Nonalcoholic Fatty Liver Disease. World Journal of Gastroenterology, 20, 9026-9037.
|
[13]
|
吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
|
[14]
|
王燕芳, 赵杰, 周少英, 师艳艳. Forns指数、FIB-4、APRI、GPR对HBV感染合并非酒精性脂肪肝病患者肝纤维化的诊断效能分析[J]. 解放军医药杂志, 2021, 33(7): 72-77.
|
[15]
|
Lee, Y.-H., Kim, S.U., Song, K.J., et al. (2016) Sarcopenia Is Associated with Significant Liver Fibrosis Independently of Obesity and Insulin Resistance in Nonalcoholic Fatty Liv-er Disease: Nationwide Surveys (KNHANES 2008-2011). Hepatology, 63, 776-786. https://doi.org/10.1002/hep.28376
|
[16]
|
Nobili, V., Alisi, A., Valenti, L., et al. (2019) NAFLD in Children: New Genes, New Diagnostic Modalities and New Drugs. Nature Reviews. Gastroenterology & Hepatology, 16, 517-530. https://doi.org/10.1038/s41575-019-0169-z
|
[17]
|
Sun, W.J., Cui, H.L., Li, N., et al. (2016) Comparison of FIB-4 Index, NAFLD Fibrosis Score and BARD Score for Prediction of Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease: A Meta-Analysis Study. Hepatology Research, 46, 862-870. https://doi.org/10.1111/hepr.12647
|
[18]
|
非酒精性脂肪性肝病防治指南(2018年更新版) [J]. 临床肝胆病杂志, 2018, 34(5): 947-957.
|
[19]
|
Xiao, G.Q., Zhu, S.X., Xiao, X., Yan, L.N., Yang, J.Y. and Wu, G. (2017) Comparison of Laboratory Tests, Ultrasound, or Magnetic Resonance Elastography to Detect Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Hepatology, 66, 1486-1501. https://doi.org/10.1002/hep.29302
|
[20]
|
Wai, C.-T., Greenson, J.K., Fontana, R.J., Kalbfleisch, J.D., Marrero, J.A., Conjeevaram, H.S. and Lok, A.S.-F. (2003) A Simple Noninvasive Index Can Predict both Significant Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C. Hepatology, 38, 518-526. https://doi.org/10.1053/jhep.2003.50346
|
[21]
|
李广平, 张红心, 张蕾, 周鹏翔, 王亚囡. 透明质酸、IV型胶原、APRI及纤维蛋白原-4对乙型肝炎后肝纤维化的诊断价值[J]. 临床和实验医学杂志, 2021, 20(13): 1385-1388.
|
[22]
|
许贞贞, 李仪, 徐冬新. APRI评分、FIB-4指数、GPR指数及RPR指数联合血栓弹力图检测对早期肝硬化的诊断价值[J]. 现代实用医学, 2022, 34(4): 540-541.
|
[23]
|
Amernia, B., Moosavy, S.H., Ba-nookh, F. and Zoghi, G. (2021) FIB-4, APRI, and AST/ALT Ratio Compared to FibroScan for the Assessment of He-patic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease in Bandar Abbas, Iran. BMC Gastroenterology, 21, Article No. 453. https://doi.org/10.1186/s12876-021-02038-3
|
[24]
|
Rigamonti, A.E., Bondesan, A., Rondinelli, E., Cella, S.G. and Sartorio, A. (2022) The Role of Aspartate Transaminase to Platelet Ratio Index (APRI) for the Prediction of Non-Alcoholic Fatty Liver Disease (NAFLD) in Severely Obese Children and Adolescents. Metabolites, 12, Article No. 155. https://doi.org/10.3390/metabo12020155
|
[25]
|
Zhang, S.J., Du, T.T., Zhang, J.H., Lu, H.M., Lin, X., Xie, J.H., Yang, Y. and Yu, X.F. (2017) The Triglyceride and Glucose Index (TyG) Is an Effective Biomarker to Identify Nonalcoholic Fatty Liver Disease. Lipids in Health and Disease, 16, Article No. 15. https://doi.org/10.1186/s12944-017-0409-6
|
[26]
|
Cazzo, E., Jimenez, L.S., Gestic, M.A., et al. (2018) Type 2 Dia-betes Mellitus and Simple Glucose Metabolism Parameters May Reliably Predict Nonalcoholic Fatty Liver Disease Fea-tures. Obesity Surgery, 28, 187-194.
https://doi.org/10.1007/s11695-017-2829-9
|
[27]
|
Simental-Mendía, L.E., Rodríguez-Morán, M. and Guerre-ro-Romero, F. (2008) The Product of Fasting Glucose and Triglycerides as Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects. Metabolic Syndrome and Related Disorders, 6, 299-304. https://doi.org/10.1089/met.2008.0034
|
[28]
|
Alizargar, J., Bai, C.‑H., Hsieh, N.‑C. and Wu, S.‑F.V. (2020) Use of the Triglyceride-Glucose Index (TyG) in Cardiovascular Disease Patients. Cardiovascular Diabetology, 19, Article No. 8. https://doi.org/10.1186/s12933-019-0982-2
|
[29]
|
Tutunchi, H., Naeini, F., Mobasseri, M. and Ostadrahimi, A. (2021) Triglyceride Glucose (TyG) Index and the Progression of Liver Fibrosis: A Cross-Sectional Study. Clinical Nu-trition ESPEN, 44, 483-487.
https://doi.org/10.1016/j.clnesp.2021.04.025
|
[30]
|
Khamseh, M.E., Malek, M., Abbasi, R., et al. (2021) Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circum-ference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity. Metabolic Syn-drome and Related Disorders, 19, 167-173.
https://doi.org/10.1089/met.2020.0109
|
[31]
|
Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C. and Ratziu, V. (2014) Performance and Limitations of Steatosis Biomarkers in Patients with Nonalcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 40, 1209-1222. https://doi.org/10.1111/apt.12963
|
[32]
|
Peng, H.Y., Pan, L., Ran, S.M., Wang, M.Y., Huang, S.X., Zhao, M., Cao, Z.M., Yao, Z.A., Xu, L., Yang, Q. and Lv, W.L. (2023) Pre-diction of MAFLD and NAFLD Using Different Screening Indexes: A Cross-Sectional Study in U.S. Adults. Frontiers in Endocrinology, 14, Article ID: 1083032. https://doi.org/10.3389/fendo.2023.1083032
|
[33]
|
Wang, J., Yan, S.M., Cui, Y.N., Chen, F.N., Piao, M.H. and Cui, W.W. (2022) The Diagnostic and Prognostic Value of the Triglycer-ide-Glucose Index in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Me-ta-Analysis. Nutrients, 14, Article No. 4969. https://doi.org/10.3390/nu14234969
|
[34]
|
Lee, J.-H., Kim, D., Kim, H.J., Lee, C.-H., et al. (2010) Hepatic Steatosis Index: A Simple Screening Tool Reflecting Nonalcoholic Fatty Liver Disease. Digestive and Liver Disease, 42, 503-508. https://doi.org/10.1016/j.dld.2009.08.002
|
[35]
|
Long, M.T., Gandhi, S. and Loomba, R. (2020) Advances in Non-Invasive Biomarkers for the Diagnosis and Monitoring of Non-Alcoholic Fatty Liver Disease. Metabolism, 111, Article ID: 154259.
https://doi.org/10.1016/j.metabol.2020.154259
|
[36]
|
Wada, T. and Zeniya, M. (2015) Background of the FIB-4 In-dex in Japanese Non-Alcoholic Fatty Liver Disease. Internal Medicine, 54, 127-132. https://doi.org/10.2169/internalmedicine.54.2685
|